Abstract
In November 2013, the Kidney Disease: Improving Global Outcomes Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease was published, recommending statins for all individuals 50 years or older with an estimated glomerular filtration rate below 60 ml/min/1.73 m2 to lower the risk of major cardiovascular events. We quantified the prevalence of statin use among the target population before and after the guideline publication in a large Danish cohort of individuals with an estimated glomerular filtration rate below 60 ml/min/1.73 m2, to investigate the effect of the guideline, but found no difference in the prevalence of statin use prior to and after the guideline publication.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Basic & Clinical Pharmacology & Toxicology |
| Vol/bind | 131 |
| Udgave nummer | 5 |
| Sider (fra-til) | 306-310 |
| ISSN | 1742-7835 |
| DOI | |
| Status | Udgivet - nov. 2022 |
Bibliografisk note
Funding Information:JDK has no conflicts of interest to declare. MN has no conflicts of interest to declare. FB has no conflicts of interest to declare. HS reports personal fees from Bristol‐Myers‐Squibb, personal fees from Novartis and personal fees from Roche, outside the submitted work. He has personally received fees from Atrium education, the Danish Pharmaceutical Industry Association, for teaching a pharmacoepidemiology course. PD has no conflicts of interest to declare. DH has no conflicts of interest to declare. LCL reports participation in research projects funded by Menarini Pharmaceuticals and LEO Pharma with funds paid to the institution where he was employed.
Publisher Copyright:
© 2022 The Authors. Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).